197 related articles for article (PubMed ID: 1386002)
1. Passive tumor targeting of soluble macromolecules and drug conjugates.
Seymour LW
Crit Rev Ther Drug Carrier Syst; 1992; 9(2):135-87. PubMed ID: 1386002
[TBL] [Abstract][Full Text] [Related]
2. SMANCS.
Duncan R
Jpn J Cancer Res; 1995 Jun; 86(6):inside front cover. PubMed ID: 7622412
[No Abstract] [Full Text] [Related]
3. [Recent advances in research on SMANCS].
Maeda H
Gan To Kagaku Ryoho; 1998 Feb; 25 Suppl 1():1-9. PubMed ID: 9512680
[TBL] [Abstract][Full Text] [Related]
4. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect.
Maeda H; Bharate GY; Daruwalla J
Eur J Pharm Biopharm; 2009 Mar; 71(3):409-19. PubMed ID: 19070661
[TBL] [Abstract][Full Text] [Related]
5. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting.
Greish K
Methods Mol Biol; 2010; 624():25-37. PubMed ID: 20217587
[TBL] [Abstract][Full Text] [Related]
6. [Tumor-targeted chemotherapy with lipid contrast medium and macro molecular anticancer agents theoretical considerations and clinical outcome].
Maeda H; Konno T
Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 2):773-82. PubMed ID: 2985005
[TBL] [Abstract][Full Text] [Related]
7. Intracavitary administration: pharmacokinetic advantages of macromolecular anticancer agents against peritoneal and pleural carcinomatoses.
Kimura M; Konno T; Miyamoto Y; Kojima Y; Maeda H
Anticancer Res; 1998; 18(4A):2547-50. PubMed ID: 9703908
[TBL] [Abstract][Full Text] [Related]
8. Factors and mechanism of "EPR" effect and the enhanced antitumor effects of macromolecular drugs including SMANCS.
Fang J; Sawa T; Maeda H
Adv Exp Med Biol; 2003; 519():29-49. PubMed ID: 12675206
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS.
Maeda H; Sawa T; Konno T
J Control Release; 2001 Jul; 74(1-3):47-61. PubMed ID: 11489482
[TBL] [Abstract][Full Text] [Related]
10. SMA-doxorubicin, a new polymeric micellar drug for effective targeting to solid tumours.
Greish K; Sawa T; Fang J; Akaike T; Maeda H
J Control Release; 2004 Jun; 97(2):219-30. PubMed ID: 15196749
[TBL] [Abstract][Full Text] [Related]
11. Poly(ethylene glycol)-poly(ester-carbonate) block copolymers carrying PEG-peptidyl-doxorubicin pendant side chains: synthesis and evaluation as anticancer conjugates.
Andersson L; Davies J; Duncan R; Ferruti P; Ford J; Kneller S; Mendichi R; Pasut G; Schiavon O; Summerford C; Tirk A; Veronese FM; Vincenzi V; Wu G
Biomacromolecules; 2005; 6(2):914-26. PubMed ID: 15762660
[TBL] [Abstract][Full Text] [Related]
12. [SMANCS/lipiodol].
Maeda H
Gan To Kagaku Ryoho; 1994 May; 21(6):907-13. PubMed ID: 8185354
[TBL] [Abstract][Full Text] [Related]
13. Elevating blood pressure as a strategy to increase tumor-targeted delivery of macromolecular drug SMANCS: cases of advanced solid tumors.
Nagamitsu A; Greish K; Maeda H
Jpn J Clin Oncol; 2009 Nov; 39(11):756-66. PubMed ID: 19596662
[TBL] [Abstract][Full Text] [Related]
14. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.
Matsumura Y; Maeda H
Cancer Res; 1986 Dec; 46(12 Pt 1):6387-92. PubMed ID: 2946403
[TBL] [Abstract][Full Text] [Related]
15. [Principle and therapeutic effect of lipophilic anticancer agent [SMANCS/lipiodol]: selective targeting with oily contrast medium].
Maeda H
Gan To Kagaku Ryoho; 1989 Oct; 16(10):3323-31. PubMed ID: 2552930
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effects of SMANCS on rat mammary tumor induced by 7,12-dimethylbenz[a]anthracene.
Kimoto A; Konno T; Kawaguchi T; Miyauchi Y; Maeda H
Cancer Res; 1992 Feb; 52(4):1013-7. PubMed ID: 1531320
[TBL] [Abstract][Full Text] [Related]
17. Exploiting the enhanced permeability and retention effect for tumor targeting.
Iyer AK; Khaled G; Fang J; Maeda H
Drug Discov Today; 2006 Sep; 11(17-18):812-8. PubMed ID: 16935749
[TBL] [Abstract][Full Text] [Related]
18. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy.
Maeda H
Adv Drug Deliv Rev; 2001 Mar; 46(1-3):169-85. PubMed ID: 11259839
[TBL] [Abstract][Full Text] [Related]
19. Role of natural killer cells and macrophages in the nonspecific resistance to tumors in mice stimulated with SMANCS, a polymer-conjugated derivative of neocarzinostatin.
Suzuki F; Pollard RB; Uchimura S; Munakata T; Maeda H
Cancer Res; 1990 Jul; 50(13):3897-904. PubMed ID: 2141295
[TBL] [Abstract][Full Text] [Related]
20. Copoly(styrene-maleic acid)-pirarubicin micelles: high tumor-targeting efficiency with little toxicity.
Greish K; Nagamitsu A; Fang J; Maeda H
Bioconjug Chem; 2005; 16(1):230-6. PubMed ID: 15656596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
